Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms
Status:
Not yet recruiting
Trial end date:
2028-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to learn the effects of treatment with an investigational drug,
CPX-351 in patients with secondary myeloid neoplasms (SMNs).